Postoperative Management

  • Chung Hee Baek


For successful kidney transplantation in sensitized patients, more immunosuppressive method such as rituximab and plasmapheresis are used. Therefore, proper prevention and monitoring of infectious disease is very important in sensitized kidney transplantation.

Although the infectious risks might be different according to the desensitization protocols and the methods of prophylaxis, higher incidences of urinary tract infection, pneumocystis pneumonia, and viral infections such as BK virus, cytomegalovirus, and herpes virus have been reported (Morath et al., Front Immunol. 8:234, 2017). Our center data showed that cytomegalovirus infection and pneumonia occurred more often in ABO-incompatible kidney transplant recipients than ABO-compatible kidney transplant recipients (Baek et al., Nephron Extra. 2(1):66–75, 2012; Kwon et al., Medicine. 95(32):e4249, 2016). However, infectious risk was not increased in ABO-incompatible and HLA-sensitized kidney transplantation after modification of immunosuppressive protocol with reducing immunosuppression (Baek et al., BMC Nephrol. 16:201, 2015). In a recent meta-analysis study (de Weerd and Betjes. Clin J Am Soc Nephrol 13:1234–43, 2018), severe non-viral infection such as sepsis, pneumonia, and fungal infection was more common in ABO-incompatible kidney transplant recipients (RR, 1.44; 95% confidence interval, 1.13–1.82; P = 0.003; I2 = 39%; P = 0.06). CMV viremia and BK viremia occurred more often in ABO-incompatible kidney transplantation (RR, 1.20; 95% confidence interval, 1.04–1.37; P = 0.01; I2 = 17%; P = 0.26 for CMV viremia and RR, 1.70; 95% confidence interval, 1.14–2.56; P = 0.01; I2 = 45%; P = 0.03 for BKV viremia).

More delicate monitoring and preventive strategies might be necessary for sensitized kidney transplantation. Because there is no guidelines for this special group, modification and applying general guidelines to sensitized patients according to individualized clinical situation is necessary. In addition, common medical problems such as hypertension, dyslipidemia, and hyperglycemia should be controlled well for better transplantation outcomes. In this chapter, postoperative infection monitoring and management and general medical care were reviewed.


Infection Hyperglycemia Dyslipidemia Hypertension 


  1. 1.
    Fehr T, Cippa PE, Mueller NJ. Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy? Transpl Int. 2015;28(12):1351–6. Scholar
  2. 2.
    Razonable RR, Humar A, Practice ASTIDCo. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93–106. Scholar
  3. 3.
    Vanichanan J, Udomkarnjananun S, Avihingsanon Y, Jutivorakool K. Common viral infections in kidney transplant recipients. Kidney Res Clin Pract. 2018;37(4):323–37. Scholar
  4. 4.
    Leeaphorn N, Garg N, Thamcharoen N, Khankin EV, Cardarelli F, Pavlakis M. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis. Am J Transplant. 2019;19(2):573–84. Scholar
  5. 5.
    Hirsch HH, Randhawa P, ASTIDCo P. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):179–88. Scholar
  6. 6.
    Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155. Scholar
  7. 7.
    Baek CH, Kim H, Yu H, Yang WS, Han DJ, Park SK. Risk factors of acute rejection in patients with BK nephropathy after reduction of immunosuppression. Ann Transplant. 2018;23:704–12. Scholar
  8. 8.
    Kim H, Yu H, Baek CH, Han DJ, Park SK. High-dose steroid therapy in BK viremia adversely affected the long-term graft function after kidney transplantation. Transpl Infect Dis. 2016;18(6):844–9. Scholar
  9. 9.
    Gabardi S, Pavlakis M, Tan C, Francis J, Cardarelli F, Asch W, et al. New England BK consortium: regional survey of BK screening and management protocols in comparison to published consensus guidelines. Transpl Infect Dis. 2018:e12985. Scholar
  10. 10.
    Piotti G, Gandolfini I, Palmisano A, Maggiore U. Metabolic risk profile in kidney transplant candidates and recipients. Nephrol Dial Transplant. 2018; Scholar
  11. 11.
    Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019;15(3):172–88. Scholar
  12. 12.
    Conte C, Secchi A. Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention. Acta Diabetol. 2018;55(8):763–79. Scholar
  13. 13.
    Pimentel AL, Cavagnolli G, Camargo JL. Diagnostic accuracy of glycated hemoglobin for post-transplantation diabetes mellitus after kidney transplantation: systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(3):565–72. Scholar
  14. 14.
    Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992–2000. Scholar
  15. 15.
    Hecking M, Haidinger M, Doller D, Werzowa J, Tura A, Zhang J, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23(4):739–49. Scholar
  16. 16.
    Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34. Scholar
  17. 17.
    Aziz F, Clark D, Garg N, Mandelbrot D, Djamali A. Hypertension guidelines: how do they apply to kidney transplant recipients. Transplant Rev. 2018;32(4):225–33. Scholar
  18. 18.
    Glicklich D, Lamba R, Pawar R. Hypertension in the kidney transplant recipient: overview of pathogenesis, clinical assessment, and treatment. Cardiol Rev. 2017;25(3):102–9. Scholar
  19. 19.
    Blanca L, Jimenez T, Cabello M, Sola E, Gutierrez C, Burgos D, et al. Cardiovascular risk in recipients with kidney transplants from expanded criteria donors. Transplant Proc. 2012;44(9):2579–81. Scholar
  20. 20.
    Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996;62(11):1588–92.CrossRefGoogle Scholar
  21. 21.
    Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535–46. Scholar
  22. 22.
    Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood Pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269–324. Scholar
  23. 23.
    Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. Scholar
  24. 24.
    Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62(2):201–13. Scholar
  25. 25.
    Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation. 2004;78(8):1204–11.CrossRefGoogle Scholar
  26. 26.
    van Riemsdijk IC, Mulder PG, de Fijter JW, Bruijn JA, van Hooff JP, Hoitsma AJ, et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation. 2000;70(1):122–6.PubMedGoogle Scholar
  27. 27.
    Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl. 1998;68:S130–4.CrossRefGoogle Scholar
  28. 28.
    Morales JM, Rodriguez-Paternina E, Araque A, Andres A, Hernandez E, Ruilope LM, et al. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5-year prospective randomized study. Transplant Proc. 1994;26(5):2598–9.PubMedGoogle Scholar
  29. 29.
    Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant. 2007;7(10):2350–60. Scholar
  30. 30.
    Knoll GA, Fergusson D, Chasse M, Hebert P, Wells G, Tibbles LA, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(4):318–26. Scholar
  31. 31.
    Hiremath S, Fergusson DA, Fergusson N, Bennett A, Knoll GA. Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2017;69(1):78–86. Scholar
  32. 32.
    Formica RN Jr, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant. 2006;21(5):1389–94. Scholar
  33. 33.
    Jennings DL, Taber DJ. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother. 2008;42(1):116–20. Scholar
  34. 34.
    Glicklich D, Gordillo R, Supe K, Tapia R, Woroniecki R, Solorzano C, et al. Angiotensin converting enzyme inhibitor use soon after renal transplantation: a randomized, double-blinded placebo-controlled safety study. Clin Transpl. 2011;25(6):843–8. Scholar
  35. 35.
    Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int. 2003;16(5):313–20. Scholar
  36. 36.
    Aftab W, Varadarajan P, Rasool S, Kore A, Pai RG. Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients. J Am Heart Assoc. 2013;2(1):e000091. Scholar
  37. 37.
    Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727–49. Scholar
  38. 38.
    Bulbul MC, Dagel T, Afsar B, Ulusu NN, Kuwabara M, Covic A, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purif. 2018;46(2):144–52. Scholar
  39. 39.
    Agarwal A, Prasad GV. Post-transplant dyslipidemia: mechanisms, diagnosis and management. World J Transplant. 2016;6(1):125–34. Scholar
  40. 40.
    Habbig S, Volland R, Krupka K, Querfeld U, Dello Strologo L, Noyan A, et al. Dyslipidemia after pediatric renal transplantation-the impact of immunosuppressive regimens. Pediatr Transplant. 2017;21(3) Scholar
  41. 41.
    Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–31. Scholar
  42. 42.
    Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929–36. Scholar
  43. 43.
    Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2009;(2):CD005019.
  44. 44.
    Lim AK, Manley KJ, Roberts MA, Fraenkel MB. Fish oil for kidney transplant recipients. Cochrane Database Syst Rev. 2016;(8):CD005282.
  45. 45.
    Morath C, Zeier M, Dohler B, Opelz G, Susal C. ABO-incompatible kidney transplantation. Front Immunol. 2017;8:234. Scholar
  46. 46.
    Baek CH, Yang WS, Park KS, Han DJ, Park JB, Park SK. Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation. Nephron Extra. 2012;2(1):66–75. Scholar
  47. 47.
    Kwon H, Kim YH, Choi JY, Sung S, Jung JH, Park SK, et al. Analysis of 4000 kidney transplantations in a single center: across immunological barriers. Medicine. 2016;95(32):e4249. Scholar
  48. 48.
    Baek CH, Kim H, Yu H, Shin E, Cho H, Yang WS, et al. Low dose of mycophenolate mofetil is enough in desensitized kidney transplantation using rituximab. BMC Nephrol. 2015;16:201. Scholar
  49. 49.
    de Weerd AE, Betjes MGH. ABO-incompatible kidney transplant outcomes: a meta-analysis. Clin J Am Soc Nephrol. 2018;13(8):1234–43. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Chung Hee Baek
    • 1
  1. 1.Division of Nephrology, Department of Internal Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea

Personalised recommendations